EUVIMEDEUVIMED entdecken
Open Access

Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy

Yishuang Li, Zhihong Zhou, Yonghui Lv, Haoneng Hu, Ming Chen, Kunjian Lei, Chuandong Gong, Junzhe Liu, Lufei Yang, Linzhen Huang, Wenji Liu, Jinying Li und 3 weitere

Theranostics · 2026

DOI: 10.7150/thno.114005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Yishuang Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The 2nd affiliated hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Endocytosis, Receptors, Chimeric Antigen, Membrane Proteins, Clathrin. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

T cell exhaustion, mediated by the expression of inhibitory receptor proteins, significantly reduces their anti-tumor efficacy. Therefore, strategies aimed at degrading membrane proteins have emerged as promising approaches for enhancing the therapeutic effectiveness of Chimeric Antigen Receptor (CAR) T cells and improving cancer treatment outcomes.

Methods

In this study, we developed a Clathrin-Mediated Endocytosis Targeting Chimera (CleTAC), an innovative platform designed to facilitate membrane protein degradation via the clathrin-mediated endocytosis pathway. CleTAC employs the YVKM motif to interact with the AP2 complex, driving the internalization of targeted membrane proteins (proteins of interest, POI) along with associated cell membrane components. These internalized complexes are subsequently trafficked to lysosomes for degradation. We conducted multiple validations using flow cytometry, Western blotting, and in vitro and in vivo experiments to verify its degradation efficiency. Additionally, we integrated CleTAC targeting CTLA4 membrane proteins into a CAR construct and evaluated its impact on CAR-T cell functionality and tumor suppressive efficacy using both cellular assays and animal tumor models.

Results

We demonstrated that CleTAC effectively and specifically mediates the degradation of EGFP and CTLA4 proteins on the cell surface. When incorporated into a CAR construct, CleTAC targeting CTLA4 enhanced CAR-T cell anti-tumor activity, as evidenced by improved functional assays and tumor suppression in animal models. These findings establish CleTAC as a versatile and effective tool for modulating membrane protein levels and enhance anti-tumor efficacy in CAR-T cells.

Conclusions

Our results highlight CleTAC as a promising therapeutic tool with substantial clinical potential to significantly enhance CAR-T cell therapy and advance current oncology treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndocytosisReceptors, Chimeric AntigenMembrane ProteinsClathrinImmunotherapy, AdoptiveT-LymphocytesNeoplasmsAnimalsHumansMiceCell Line, TumorProteolysisCTLA-4 AntigenXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

CAR-T cell therapyCancer therapyCleTACEndocytosis degradationTargeted protein degradation

Substanzen

Receptors, Chimeric AntigenMembrane ProteinsClathrinCTLA-4 Antigen

Autor:innen und Institutionen

  • Department of Neurosurgery, The 2nd affiliated hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Province Key Laboratory of Neurological Diseases, Nanchang, China.
  • JXHC key Laboratory of Neurological medicine, Nanchang, China.
  • Institute of Neuroscience, Nanchang University, Nanchang, China.
  • The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, The 2nd Affiliated hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Second Clinical Medical School, Jiangxi Medical College, Nanchang University, Nanchang, China.

Zitieren

APA

Li, Y., Zhou, Z., Lv, Y., Hu, H., Chen, M., Lei, K., Gong, C., Liu, J., Yang, L., Huang, L., Liu, W., Li, J., Ye, M., Zhu, X., & Huang, K. (2026). Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy. Theranostics. https://doi.org/10.7150/thno.114005

Vancouver

Li Y, Zhou Z, Lv Y, Hu H, Chen M, Lei K, et al. Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy. Theranostics. 2026. doi:10.7150/thno.114005

BibTeX
@article{Li2026,
  author = {Li, Yishuang and Zhou, Zhihong and Lv, Yonghui and Hu, Haoneng and Chen, Ming and Lei, Kunjian and Gong, Chuandong and Liu, Junzhe and Yang, Lufei and Huang, Linzhen and Liu, Wenji and Li, Jinying and Ye, Minhua and Zhu, Xingen and Huang, Kai},
  title = {Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.114005}
}
Kostenlos starten →